Grace Therapeutics (GRCE) AI Stock Analysis

• Market Cap: $37.18M
• Dividend Yield: N/A
• Average Volume (3M): 23.32K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.02
• Revenue Growth: N/A
• EPS Growth: 75.74%
• Country: US
• Employees: 4
• Sector: Healthcare
• Sector Strength: 58
• Industry: Biotechnology
• EPS (TTM): -1.24
• Shares Outstanding: 13,718,106
• 10 Day Avg. Volume: 14,294
• 30 Day Avg. Volume: 23,320
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.52
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $11.67
• Price Target Upside: 283.88% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

Grace Therapeutics is navigating a challenging financial landscape, marked by no revenue and persistent operational losses, which are somewhat mitigated by a strong equity base and absence of debt. The stock shows positive technical momentum but is at risk of being overbought. The negative P/E ratio highlights the risk associated with the company's current financial performance and lack of earnings. Strategic management is required to improve operational viability and financial sustainability.

Positive Factors

Clinical Outcomes

GTX-104 showed indications of improved outcomes with more patients having 'good recovery' at Day-90 follow-up on the aSAH modified Rankin scale.

Market Potential

Analyst believes GTX-104 is a potential new gold-standard for post-surgical aSAH standard of care in the ICU vs. current parenteral nimodipine.

Regulatory Progress

Acasti secured agreement from the FDA on a streamlined approach with an open-label pivotal safety trial.

Negative Factors

Safety Concerns

There were more deaths in the GTX-104 arm compared to the oral nimodipine arm, but no deaths were attributed to nimodipine therapy.

Grace Therapeutics Business Overview & Revenue Model

Company Description

Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.

How the Company Makes Money

Grace Therapeutics makes money primarily through the development and commercialization of its proprietary therapeutic products. The company generates revenue by selling its approved drugs to healthcare providers, hospitals, and specialty pharmacies. Key revenue streams include product sales, licensing agreements, and strategic partnerships with other pharmaceutical companies. These partnerships often involve collaboration on research and development efforts, as well as co-marketing and distribution agreements that expand the reach of Grace's products. Additionally, the company may receive milestone payments and royalties from out-licensed products and technologies that are successfully commercialized by its partners.

Grace Therapeutics Financial Statement Overview

Summary

Grace Therapeutics faces significant challenges with no revenue and persistent losses, raising sustainability concerns. The strong equity base and lack of debt provide some support, but the cash flow situation necessitates strategic financial management to secure future funding and ensure operational viability.

Income Statement

Grace Therapeutics shows no revenue generation over the past periods, which is concerning for financial health. The consistent negative EBIT and EBITDA margins indicate ongoing operational losses. The absence of revenue growth further exacerbates the situation, reflecting challenges in product development or market penetration.

Balance Sheet

The company maintains a strong equity position, with a favorable equity ratio above 85% in the latest TTM. The absence of debt reduces financial risk, but the declining total assets and equity could indicate potential liquidity pressures in the future.

Cash Flow

Negative operating and free cash flows highlight ongoing cash burn, typical in early-stage biotech firms. However, cash reserves have been managed to cover short-term needs, albeit with decreasing cash flow from financing activities, suggesting potential funding challenges ahead.

Breakdown
Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Income Statement		Total Revenue
0.00	0.00	0.00	196.00K	0.00
	Gross Profit
0.00	0.00	0.00	120.00K	0.00
	EBIT
-12.85M	-52.16M	-15.59M	-16.42M	-24.44M
	EBITDA
-11.33M	-18.12M	-15.34M	-9.79M	-22.95M
	Net Income Common Stockholders
-12.85M	-42.43M	-9.82M	-19.68M	-25.51M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
23.00M	27.89M	43.66M	60.73M	14.24M
	Total Assets
73.30M	79.12M	128.62M	62.46M	22.85M
	Total Debt
0.00	485.00K	295.00K	86.00K	147.00K
	Net Debt
-23.00M	-27.39M	-30.04M	-50.86M	-14.09M
	Total Liabilities
11.56M	11.17M	20.35M	6.80M	9.86M
	Stockholders Equity
61.74M	67.95M	108.27M	55.66M	12.99M
Cash Flow		Free Cash Flow
-12.36M	-15.93M	-17.23M	-14.39M	-23.27M
	Operating Cash Flow
-12.33M	-15.91M	-17.23M	-14.32M	-22.95M
	Investing Cash Flow
104.00K	13.15M	-3.52M	-9.86M	8.14M
	Financing Cash Flow
7.36M	304.00K	0.00	59.49M	13.18M

Grace Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 3.04
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GRCE, the sentiment is Neutral. The current price of 3.04 is above the 20-day moving average (MA) of 2.21, above the 50-day MA of 2.44, and above the 200-day MA of 2.99, indicating a neutral trend. The MACD of 0.05 indicates Negative momentum. The RSI at 65.89 is Neutral, neither overbought nor oversold. The STOCH value of 96.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GRCE.

Grace Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.36B	3.88	-42.93%	2.87%	17.85%	1.45%
GRCE	46 Neutral	$37.18M	―	-22.89%	―	―	75.74%
PYPD	41 Neutral	$28.43M	―	-1038.73%	―	―	34.97%
GBIO	38 Underperform	$29.21M	―	-91.02%	―	236.92%	-0.57%
INKT	38 Underperform	$30.14M	―	78.50%	―	―	55.52%
CVKD	32 Underperform	$32.01M	―	-140.78%	―	―	16.20%
ALGS	30 Underperform	$34.24M	―	-415.84%	―	-74.60%	―